Profile data is unavailable for this security.
About the company
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
- Revenue in USD (TTM)1.75m
- Net income in USD-21.03m
- Incorporated2014
- Employees35.00
- LocationBeyondspring Inc100 Campus DriveWest Side, 4Th Floor, Suite 410FLORHAM PARK 07932United StatesUSA
- Phone+1 (646) 528-4184
- Websitehttps://www.beyondspringpharma.com/en/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 92.82m | 35.00 | 411.76 | 366.59 | -- | 37.22 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| Anixa Biosciences Inc | 210.00k | -10.74m | 92.83m | 4.00 | -- | 3.76 | -- | 442.04 | -0.3451 | -0.3451 | 0.0068 | 0.7749 | 0.0078 | -- | 0.7807 | 52,500.00 | -40.49 | -59.69 | -41.26 | -62.61 | -- | -- | -5,174.29 | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
| Curis Inc | 10.02m | -47.41m | 95.48m | 48.00 | -- | 4.85 | -- | 9.53 | -9.02 | -9.02 | 1.89 | 3.34 | 0.1077 | -- | 3.47 | 208,812.50 | -50.95 | -37.25 | -58.32 | -41.12 | 97.88 | 96.05 | -473.04 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 95.49m | 91.00 | -- | 0.6723 | -- | 3.07 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Eton Pharmaceuticals Inc | 31.64m | -936.00k | 95.56m | 30.00 | -- | 6.17 | -- | 3.02 | -0.0389 | -0.0389 | 1.23 | 0.6025 | 1.11 | 14.42 | 12.02 | 1,054,733.00 | -3.30 | -46.22 | -5.49 | -58.20 | 66.56 | 72.16 | -2.96 | -76.86 | 1.60 | -- | 0.258 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
| Clearside Biomedical Inc | 8.23m | -32.49m | 95.66m | 30.00 | -- | -- | -- | 11.63 | -0.5263 | -0.5263 | 0.1331 | -0.2532 | 0.1928 | -- | 96.78 | 274,200.00 | -76.15 | -63.57 | -89.34 | -81.77 | 95.64 | -- | -394.91 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Oramed Pharmaceuticals, Inc. | 1.34m | 5.53m | 97.25m | 15.00 | 18.90 | 0.591 | 18.40 | 72.57 | 0.1270 | 0.1270 | 0.033 | 4.06 | 0.007 | -- | -- | 89,333.34 | 2.66 | -- | 3.13 | -- | -- | -- | 379.70 | -- | -- | -- | 0.2385 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Passage Bio Inc | 0.00 | -102.06m | 97.35m | 58.00 | -- | 0.7801 | -- | -- | -1.87 | -1.87 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -51.80 | -48.56 | -56.80 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Genelux Corp | 170.00k | -28.30m | 98.06m | 23.00 | -- | 4.94 | -- | 576.82 | -1.22 | -1.22 | 0.007 | 0.7389 | 0.0102 | -- | -- | 7,391.30 | -169.32 | -- | -- | -- | -- | -- | -16,645.29 | -- | -- | -6.48 | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Beyondspring Inc | 1.75m | -21.03m | 99.13m | 35.00 | -- | -- | -- | 56.62 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| IO Biotech Inc | 0.00 | -86.08m | 101.46m | 68.00 | -- | 0.7619 | -- | -- | -2.15 | -2.15 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -56.91 | -- | -62.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 4.53m | -69.05m | 103.40m | 66.00 | -- | -- | -- | 22.83 | -1.91 | -1.91 | 0.1255 | -0.8877 | 0.0466 | -- | -- | 68,621.21 | -71.11 | -59.78 | -90.34 | -72.70 | -- | -- | -1,524.51 | -1,113.72 | -- | -1.68 | 1.64 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Nanopharmaceutics Inc | 1.01m | -549.47k | 104.40m | 50.00 | -- | -- | -- | 103.41 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -27.03m | 105.09m | 28.00 | -- | 2.13 | -- | -- | -0.5642 | -0.5642 | 0.00 | 0.7889 | 0.00 | -- | -- | 0.00 | -47.51 | -38.31 | -56.21 | -43.34 | -- | -- | -- | -- | -- | -6.33 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Assertio Holdings Inc | 152.07m | -331.94m | 105.59m | 53.00 | -- | 0.7615 | -- | 0.6943 | -3.97 | -3.97 | 2.04 | 1.46 | 0.4343 | 1.04 | 3.27 | 2,869,227.00 | -94.80 | -21.51 | -129.77 | -32.05 | 82.36 | 88.68 | -218.28 | -62.10 | 1.43 | -- | 0.2182 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
Data as of May 08 2024. Currency figures normalised to Beyondspring Inc's reporting currency: US Dollar USD
1.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 116.47k | 0.30% |
| BlackRock Financial Management, Inc.as of 31 Dec 2023 | 94.58k | 0.24% |
| Group One Trading LPas of 31 Dec 2023 | 56.99k | 0.15% |
| Capstone Capital LLCas of 31 Mar 2024 | 50.50k | 0.13% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 34.80k | 0.09% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 32.20k | 0.08% |
| Tanaka Capital Management, Inc.as of 31 Dec 2023 | 29.47k | 0.08% |
| Geode Capital Management LLCas of 31 Dec 2023 | 20.18k | 0.05% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 18.57k | 0.05% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 12.42k | 0.03% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
